The Emerging Role of SSM and Other Noninvasive Modalities in the Diagnosis and Management of Portal Hypertension

By IJCP Editorial Team

Written By: user

IJCP Editorial Team

Published On: 04 Aug, 2023 6:19 PM | Updated On: 04 Aug, 2023 6:47 PM

The Emerging Role of SSM and Other Noninvasive Modalities in the Diagnosis and Management of Portal Hypertension

Portal hypertension (PHT) can be accessed via invasive or noninvasive tests.
Noninvasive tests are promising in predicting the presence of clinically significant portal hypertension (CSPH) and excluding patients not needing endoscopy. Current invasive measures for identifying patients at high risk of CSPH and decompensation include biopsy and hepatic venous pressure gradient (HVPG).
Developing noninvasive measures for the identification of patients at high risk of CSPH and decompensation includes plasma biomarkers (vWF-AG, APRI, ELF, ICG-r15), liver stiffness measurement (LSM) and spleen stiffness measurement (SSM).
SSM <21 kPa rules out CSPH, while SSM >50 kPa rules-in CSPH.
For the assessment of PHT-HVPG is the gold standard; vWF is promising; spleen stiffness is reliable, and machine learning is promising.
SSM/LSM are promising noninvasive tests for knowing the response to beta-blockers

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.